Although fatigue is a very disabling symptom, it is often not therapy decisive because you cannot measure it so far. I hope I can use my knowledge as a patient and physician and contribute to change this.
I am pleased to have a role in inspecting the workpackages, especially about the biomarkers, and I think my opinion is valued and ideas are taken seriously.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853981. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.
